| Identification | Back Directory | [Name]
punicalin | [CAS]
65995-64-4 | [Synonyms]
punicalin
PubChem ID: 5388496
PubChem ID: 5464368
4,6-Gallagylglucose
PubChem ID: 92131301
4,6-Gallagyl-D-glucose
Punicalin, mixture of anomers
D-Glucose cyclic 4,6-[(2S,2'S)-2,2'-(5,10-dihydro-2,3,7,8-tetrahydroxy-5,10-dioxo[1]benzopyrano[5,4,3-cde][1]benzopyran-1,6-diyl)bis[3,4,5-trihydroxybenzoate]]
4-O,6-O-[(aS)-[2,2'-[(5,10-Dihydro-2,3,7,8-tetrahydroxy-5,10-dioxo[1]benzopyrano[5,4,3-cde][1]benzopyran)-1,6-diyl]bis[3,4,5-trihydroxyphenyl]]dicarbonyl]-β-D-glucopyranose
Punicalin
D-Glucose cyclic 4,6-[(2S,2'S)-2,2'-(5,10-dihydro-2,3,7,8-tetrahydroxy-5,10-dioxo[1]benzopyrano[5,4,3-cde][1]benzopyran-1,6-diyl)bis[3,4,5-trihydroxybenzoate]] | [Molecular Formula]
C34H22O22 | [MDL Number]
MFCD09838018 | [MOL File]
65995-64-4.mol | [Molecular Weight]
782.526 |
| Chemical Properties | Back Directory | [Boiling point ]
1548.3±65.0 °C(Predicted) | [density ]
2.036 | [storage temp. ]
-20°C | [solubility ]
DMSO: soluble | [form ]
neat | [pka]
1.93±0.60(Predicted) | [color ]
Light yellow to green yellow | [Major Application]
food and beverages | [InChIKey]
IQHIEHIKNWLKFB-ITTSEVFZSA-N | [SMILES]
OC1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3-c4c(O)c(O)c5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5-c67)-c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@H](O)[C@H]1O |
| Hazard Information | Back Directory | [Uses]
Refer to the productμs Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support. | [Definition]
ChEBI: Punicalin is a tannin. | [in vivo]
Punicalin (5 mg/kg, subcutaneous injection) has an obvious anti-inflammatory effect on carrageenan (HY-125474)-induced metatarsal edema in rats[1].
Punicalin (10 mg/kg, intraperitoneal injection) alleviates LPS (HY-D1056)-induced acute lung injury in mice by inhibiting the production of inflammatory cytokines and MAPK/ NF-κB signaling[5].
| Animal Model: | Carrageenan (HY-125474)-induced Edema in rats[1] | | Dosage: | 5 mg/kg | | Administration: | s.c. | | Result: | Showed significant anti-inflammatory effect against carrageenan induced paw edema at all time intervals, but decreased the effects.with larger dose. |
| Animal Model: | LPS (HY-D1056)-induced acute lung injury mice[5] | | Dosage: | 10 mg/kg | | Administration: | i.p. | | Result: | Reduced the mortality and attenuated the severity of lung pathological injury.
Ameliorated LPS (HY-D1056)-induced lung edema and vascular leakage.
|
|
|
|